Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through: - Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) - Phase 1 in Neuro-Endocrine Tumors (NET) - Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG
View Top Employees from MimiVax, LLC| Website | http://www.mimivax.com |
| Revenue | $6 million |
| Funding | $1.6 million |
| Employees | 3 (2 on RocketReach) |
| Founded | 2012 |
| Address | Elm &, Buffalo, New York 14203, US |
| Phone | (716) 845-8850 |
| Technologies |
JavaScript,
HTML,
PHP
+12 more
(view full list)
|
| Industry | Biotechnology Research, Manufacturing General, Commercial, Immunotherapy, Manufacturing, Intellectual Property, Vaccines, Professional Services, Oncology, Real Estate, Pharmaceutical Developement |
| Web Rank | 4 Million |
| Keywords | Mimivax, Survaxm, Survaxm Mutation |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular MimiVax, LLC employee's phone or email?
MimiVax, LLC Questions
The MimiVax, LLC annual revenue was $6 million in 2023.
Michael Ciesielski is the CEO of MimiVax, LLC.
2 people are employed at MimiVax, LLC.
MimiVax, LLC is based in Buffalo, New York.
The NAICS codes for MimiVax, LLC are [325, 32541, 3254, 32].
The SIC codes for MimiVax, LLC are [283, 28].
Top MimiVax, LLC Employees
-
View
Michael Ciesielski
Chief Executive Officer at MimiVax, LLC
Orchard Park, New York, United States5+5+ -
43
Related Companies
